

Global Therapeutic Monoclonal Antibodies Drug Market Research Report 2024, Forecast to 2032

<https://marketpublishers.com/r/G7107ADF68CCEN.html>

Date: October 2024

Pages: 154

Price: US\$ 3,400.00 (Single User License)

ID: G7107ADF68CCEN

Abstracts

Report Overview

Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.

The global Therapeutic Monoclonal Antibodies Drug market size was estimated at USD 162410 million in 2023 and is projected to reach USD 415450.78 million by 2032, exhibiting a CAGR of 11.00% during the forecast period.

North America Therapeutic Monoclonal Antibodies Drug market size was estimated at USD 50675.85 million in 2023, at a CAGR of 9.43% during the forecast period of 2024 through 2032.

This report provides a deep insight into the global Therapeutic Monoclonal Antibodies Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Therapeutic Monoclonal Antibodies Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the

main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Therapeutic Monoclonal Antibodies Drug market in any manner.

Global Therapeutic Monoclonal Antibodies Drug Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

AbbVie

Johnson & Johnson

Novartis

Gilead Sciences

Roche

Bristol-Myers Squibb

Amgen

AstraZeneca

Merck & Co

Takeda

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer

Regeneron

Innovent

Hengrui Medicine

Market Segmentation (by Type)

Mouse-derived Antibodies

Chimeric Antibodies

Humanized Antibodies

Market Segmentation (by Application)

Immune Diseases

Cancer

Other

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-

Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Therapeutic Monoclonal Antibodies Drug Market

Overview of the regional outlook of the Therapeutic Monoclonal Antibodies Drug Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Therapeutic Monoclonal Antibodies Drug Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Therapeutic Monoclonal Antibodies Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

- 1.1 Market Definition and Statistical Scope of Therapeutic Monoclonal Antibodies Drug
- 1.2 Key Market Segments
 - 1.2.1 Therapeutic Monoclonal Antibodies Drug Segment by Type
 - 1.2.2 Therapeutic Monoclonal Antibodies Drug Segment by Application
- 1.3 Methodology & Sources of Information
 - 1.3.1 Research Methodology
 - 1.3.2 Research Process
 - 1.3.3 Market Breakdown and Data Triangulation
 - 1.3.4 Base Year
 - 1.3.5 Report Assumptions & Caveats

2 THERAPEUTIC MONOCLONAL ANTIBODIES DRUG MARKET OVERVIEW

- 2.1 Global Market Overview
 - 2.1.1 Global Therapeutic Monoclonal Antibodies Drug Market Size (M USD) Estimates and Forecasts (2019-2032)
 - 2.1.2 Global Therapeutic Monoclonal Antibodies Drug Sales Estimates and Forecasts (2019-2032)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

3 THERAPEUTIC MONOCLONAL ANTIBODIES DRUG MARKET COMPETITIVE LANDSCAPE

- 3.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Manufacturers (2019-2024)
- 3.2 Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Manufacturers (2019-2024)
- 3.3 Therapeutic Monoclonal Antibodies Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Therapeutic Monoclonal Antibodies Drug Average Price by Manufacturers (2019-2024)
- 3.5 Manufacturers Therapeutic Monoclonal Antibodies Drug Sales Sites, Area Served, Product Type
- 3.6 Therapeutic Monoclonal Antibodies Drug Market Competitive Situation and Trends

- 3.6.1 Therapeutic Monoclonal Antibodies Drug Market Concentration Rate
- 3.6.2 Global 5 and 10 Largest Therapeutic Monoclonal Antibodies Drug Players Market Share by Revenue
- 3.6.3 Mergers & Acquisitions, Expansion

4 THERAPEUTIC MONOCLONAL ANTIBODIES DRUG INDUSTRY CHAIN ANALYSIS

- 4.1 Therapeutic Monoclonal Antibodies Drug Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF THERAPEUTIC MONOCLONAL ANTIBODIES DRUG MARKET

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Market Restraints
- 5.5 Industry News
 - 5.5.1 New Product Developments
 - 5.5.2 Mergers & Acquisitions
 - 5.5.3 Expansions
 - 5.5.4 Collaboration/Supply Contracts
- 5.6 Industry Policies

6 THERAPEUTIC MONOCLONAL ANTIBODIES DRUG MARKET SEGMENTATION BY TYPE

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2019-2024)
- 6.3 Global Therapeutic Monoclonal Antibodies Drug Market Size Market Share by Type (2019-2024)
- 6.4 Global Therapeutic Monoclonal Antibodies Drug Price by Type (2019-2024)

7 THERAPEUTIC MONOCLONAL ANTIBODIES DRUG MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Therapeutic Monoclonal Antibodies Drug Market Sales by Application (2019-2024)
- 7.3 Global Therapeutic Monoclonal Antibodies Drug Market Size (M USD) by Application (2019-2024)
- 7.4 Global Therapeutic Monoclonal Antibodies Drug Sales Growth Rate by Application (2019-2024)

8 THERAPEUTIC MONOCLONAL ANTIBODIES DRUG MARKET CONSUMPTION BY REGION

- 8.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Region
 - 8.1.1 Global Therapeutic Monoclonal Antibodies Drug Sales by Region
 - 8.1.2 Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region
- 8.2 North America
 - 8.2.1 North America Therapeutic Monoclonal Antibodies Drug Sales by Country
 - 8.2.2 U.S.
 - 8.2.3 Canada
 - 8.2.4 Mexico
- 8.3 Europe
 - 8.3.1 Europe Therapeutic Monoclonal Antibodies Drug Sales by Country
 - 8.3.2 Germany
 - 8.3.3 France
 - 8.3.4 U.K.
 - 8.3.5 Italy
 - 8.3.6 Russia
- 8.4 Asia Pacific
 - 8.4.1 Asia Pacific Therapeutic Monoclonal Antibodies Drug Sales by Region
 - 8.4.2 China
 - 8.4.3 Japan
 - 8.4.4 South Korea
 - 8.4.5 India
 - 8.4.6 Southeast Asia
- 8.5 South America
 - 8.5.1 South America Therapeutic Monoclonal Antibodies Drug Sales by Country
 - 8.5.2 Brazil
 - 8.5.3 Argentina
 - 8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 THERAPEUTIC MONOCLONAL ANTIBODIES DRUG MARKET PRODUCTION BY REGION

9.1 Global Production of Therapeutic Monoclonal Antibodies Drug by Region (2019-2024)

9.2 Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by Region (2019-2024)

9.3 Global Therapeutic Monoclonal Antibodies Drug Production, Revenue, Price and Gross Margin (2019-2024)

9.4 North America Therapeutic Monoclonal Antibodies Drug Production

9.4.1 North America Therapeutic Monoclonal Antibodies Drug Production Growth Rate (2019-2024)

9.4.2 North America Therapeutic Monoclonal Antibodies Drug Production, Revenue, Price and Gross Margin (2019-2024)

9.5 Europe Therapeutic Monoclonal Antibodies Drug Production

9.5.1 Europe Therapeutic Monoclonal Antibodies Drug Production Growth Rate (2019-2024)

9.5.2 Europe Therapeutic Monoclonal Antibodies Drug Production, Revenue, Price and Gross Margin (2019-2024)

9.6 Japan Therapeutic Monoclonal Antibodies Drug Production (2019-2024)

9.6.1 Japan Therapeutic Monoclonal Antibodies Drug Production Growth Rate (2019-2024)

9.6.2 Japan Therapeutic Monoclonal Antibodies Drug Production, Revenue, Price and Gross Margin (2019-2024)

9.7 China Therapeutic Monoclonal Antibodies Drug Production (2019-2024)

9.7.1 China Therapeutic Monoclonal Antibodies Drug Production Growth Rate (2019-2024)

9.7.2 China Therapeutic Monoclonal Antibodies Drug Production, Revenue, Price and Gross Margin (2019-2024)

10 KEY COMPANIES PROFILE

10.1 AbbVie

- 10.1.1 AbbVie Therapeutic Monoclonal Antibodies Drug Basic Information
- 10.1.2 AbbVie Therapeutic Monoclonal Antibodies Drug Product Overview
- 10.1.3 AbbVie Therapeutic Monoclonal Antibodies Drug Product Market Performance
- 10.1.4 AbbVie Business Overview
- 10.1.5 AbbVie Therapeutic Monoclonal Antibodies Drug SWOT Analysis
- 10.1.6 AbbVie Recent Developments

10.2 Johnson and Johnson

- 10.2.1 Johnson and Johnson Therapeutic Monoclonal Antibodies Drug Basic Information
- 10.2.2 Johnson and Johnson Therapeutic Monoclonal Antibodies Drug Product Overview
- 10.2.3 Johnson and Johnson Therapeutic Monoclonal Antibodies Drug Product Market Performance
- 10.2.4 Johnson and Johnson Business Overview
- 10.2.5 Johnson and Johnson Therapeutic Monoclonal Antibodies Drug SWOT Analysis
- 10.2.6 Johnson and Johnson Recent Developments

10.3 Novartis

- 10.3.1 Novartis Therapeutic Monoclonal Antibodies Drug Basic Information
- 10.3.2 Novartis Therapeutic Monoclonal Antibodies Drug Product Overview
- 10.3.3 Novartis Therapeutic Monoclonal Antibodies Drug Product Market Performance
- 10.3.4 Novartis Therapeutic Monoclonal Antibodies Drug SWOT Analysis
- 10.3.5 Novartis Business Overview
- 10.3.6 Novartis Recent Developments

10.4 Gilead Sciences

- 10.4.1 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Basic Information
- 10.4.2 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Overview
- 10.4.3 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Market Performance
- 10.4.4 Gilead Sciences Business Overview
- 10.4.5 Gilead Sciences Recent Developments

10.5 Roche

- 10.5.1 Roche Therapeutic Monoclonal Antibodies Drug Basic Information
- 10.5.2 Roche Therapeutic Monoclonal Antibodies Drug Product Overview
- 10.5.3 Roche Therapeutic Monoclonal Antibodies Drug Product Market Performance
- 10.5.4 Roche Business Overview
- 10.5.5 Roche Recent Developments

10.6 Bristol-Myers Squibb

10.6.1 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Basic Information

10.6.2 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Overview

10.6.3 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Market Performance

10.6.4 Bristol-Myers Squibb Business Overview

10.6.5 Bristol-Myers Squibb Recent Developments

10.7 Amgen

10.7.1 Amgen Therapeutic Monoclonal Antibodies Drug Basic Information

10.7.2 Amgen Therapeutic Monoclonal Antibodies Drug Product Overview

10.7.3 Amgen Therapeutic Monoclonal Antibodies Drug Product Market Performance

10.7.4 Amgen Business Overview

10.7.5 Amgen Recent Developments

10.8 AstraZeneca

10.8.1 AstraZeneca Therapeutic Monoclonal Antibodies Drug Basic Information

10.8.2 AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Overview

10.8.3 AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Market Performance

10.8.4 AstraZeneca Business Overview

10.8.5 AstraZeneca Recent Developments

10.9 Merck and Co

10.9.1 Merck and Co Therapeutic Monoclonal Antibodies Drug Basic Information

10.9.2 Merck and Co Therapeutic Monoclonal Antibodies Drug Product Overview

10.9.3 Merck and Co Therapeutic Monoclonal Antibodies Drug Product Market Performance

10.9.4 Merck and Co Business Overview

10.9.5 Merck and Co Recent Developments

10.10 Takeda

10.10.1 Takeda Therapeutic Monoclonal Antibodies Drug Basic Information

10.10.2 Takeda Therapeutic Monoclonal Antibodies Drug Product Overview

10.10.3 Takeda Therapeutic Monoclonal Antibodies Drug Product Market Performance

10.10.4 Takeda Business Overview

10.10.5 Takeda Recent Developments

10.11 Merck KGaA

10.11.1 Merck KGaA Therapeutic Monoclonal Antibodies Drug Basic Information

10.11.2 Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Overview

10.11.3 Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Market

Performance

- 10.11.4 Merck KGaA Business Overview
- 10.11.5 Merck KGaA Recent Developments

10.12 Seagen

- 10.12.1 Seagen Therapeutic Monoclonal Antibodies Drug Basic Information
- 10.12.2 Seagen Therapeutic Monoclonal Antibodies Drug Product Overview
- 10.12.3 Seagen Therapeutic Monoclonal Antibodies Drug Product Market

Performance

- 10.12.4 Seagen Business Overview
- 10.12.5 Seagen Recent Developments

10.13 Eli Lilly

- 10.13.1 Eli Lilly Therapeutic Monoclonal Antibodies Drug Basic Information
- 10.13.2 Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Overview
- 10.13.3 Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Market Performance
- 10.13.4 Eli Lilly Business Overview
- 10.13.5 Eli Lilly Recent Developments

10.14 Ono Pharmaceutical

- 10.14.1 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Basic Information
- 10.14.2 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Overview
- 10.14.3 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Market

Performance

- 10.14.4 Ono Pharmaceutical Business Overview
- 10.14.5 Ono Pharmaceutical Recent Developments

10.15 Pfizer

- 10.15.1 Pfizer Therapeutic Monoclonal Antibodies Drug Basic Information
- 10.15.2 Pfizer Therapeutic Monoclonal Antibodies Drug Product Overview
- 10.15.3 Pfizer Therapeutic Monoclonal Antibodies Drug Product Market Performance
- 10.15.4 Pfizer Business Overview
- 10.15.5 Pfizer Recent Developments

10.16 Regeneron

- 10.16.1 Regeneron Therapeutic Monoclonal Antibodies Drug Basic Information
- 10.16.2 Regeneron Therapeutic Monoclonal Antibodies Drug Product Overview
- 10.16.3 Regeneron Therapeutic Monoclonal Antibodies Drug Product Market

Performance

- 10.16.4 Regeneron Business Overview
- 10.16.5 Regeneron Recent Developments

10.17 Innovent

- 10.17.1 Innovent Therapeutic Monoclonal Antibodies Drug Basic Information
- 10.17.2 Innovent Therapeutic Monoclonal Antibodies Drug Product Overview
- 10.17.3 Innovent Therapeutic Monoclonal Antibodies Drug Product Market

Performance

- 10.17.4 Innovent Business Overview
- 10.17.5 Innovent Recent Developments

10.18 Hengrui Medicine

- 10.18.1 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Basic Information
- 10.18.2 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Overview
- 10.18.3 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Market

Performance

- 10.18.4 Hengrui Medicine Business Overview
- 10.18.5 Hengrui Medicine Recent Developments

11 THERAPEUTIC MONOCLONAL ANTIBODIES DRUG MARKET FORECAST BY REGION

- 11.1 Global Therapeutic Monoclonal Antibodies Drug Market Size Forecast
- 11.2 Global Therapeutic Monoclonal Antibodies Drug Market Forecast by Region
 - 11.2.1 North America Market Size Forecast by Country
 - 11.2.2 Europe Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country
 - 11.2.3 Asia Pacific Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Region
 - 11.2.4 South America Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country
 - 11.2.5 Middle East and Africa Forecasted Consumption of Therapeutic Monoclonal Antibodies Drug by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)

- 12.1 Global Therapeutic Monoclonal Antibodies Drug Market Forecast by Type (2025-2032)
 - 12.1.1 Global Forecasted Sales of Therapeutic Monoclonal Antibodies Drug by Type (2025-2032)
 - 12.1.2 Global Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Type (2025-2032)
 - 12.1.3 Global Forecasted Price of Therapeutic Monoclonal Antibodies Drug by Type (2025-2032)

12.2 Global Therapeutic Monoclonal Antibodies Drug Market Forecast by Application (2025-2032)

12.2.1 Global Therapeutic Monoclonal Antibodies Drug Sales (K MT) Forecast by Application

12.2.2 Global Therapeutic Monoclonal Antibodies Drug Market Size (M USD) Forecast by Application (2025-2032)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

- Table 1. Introduction of the Type
- Table 2. Introduction of the Application
- Table 3. Market Size (M USD) Segment Executive Summary
- Table 4. Therapeutic Monoclonal Antibodies Drug Market Size Comparison by Region (M USD)
- Table 5. Global Therapeutic Monoclonal Antibodies Drug Sales (K MT) by Manufacturers (2019-2024)
- Table 6. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Manufacturers (2019-2024)
- Table 7. Global Therapeutic Monoclonal Antibodies Drug Revenue (M USD) by Manufacturers (2019-2024)
- Table 8. Global Therapeutic Monoclonal Antibodies Drug Revenue Share by Manufacturers (2019-2024)
- Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Therapeutic Monoclonal Antibodies Drug as of 2022)
- Table 10. Global Market Therapeutic Monoclonal Antibodies Drug Average Price (USD/MT) of Key Manufacturers (2019-2024)
- Table 11. Manufacturers Therapeutic Monoclonal Antibodies Drug Sales Sites and Area Served
- Table 12. Manufacturers Therapeutic Monoclonal Antibodies Drug Product Type
- Table 13. Global Therapeutic Monoclonal Antibodies Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 14. Mergers & Acquisitions, Expansion Plans
- Table 15. Industry Chain Map of Therapeutic Monoclonal Antibodies Drug
- Table 16. Market Overview of Key Raw Materials
- Table 17. Midstream Market Analysis
- Table 18. Downstream Customer Analysis
- Table 19. Key Development Trends
- Table 20. Driving Factors
- Table 21. Therapeutic Monoclonal Antibodies Drug Market Challenges
- Table 22. Global Therapeutic Monoclonal Antibodies Drug Sales by Type (K MT)
- Table 23. Global Therapeutic Monoclonal Antibodies Drug Market Size by Type (M USD)
- Table 24. Global Therapeutic Monoclonal Antibodies Drug Sales (K MT) by Type (2019-2024)

Table 25. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Type (2019-2024)

Table 26. Global Therapeutic Monoclonal Antibodies Drug Market Size (M USD) by Type (2019-2024)

Table 27. Global Therapeutic Monoclonal Antibodies Drug Market Size Share by Type (2019-2024)

Table 28. Global Therapeutic Monoclonal Antibodies Drug Price (USD/MT) by Type (2019-2024)

Table 29. Global Therapeutic Monoclonal Antibodies Drug Sales (K MT) by Application

Table 30. Global Therapeutic Monoclonal Antibodies Drug Market Size by Application

Table 31. Global Therapeutic Monoclonal Antibodies Drug Sales by Application (2019-2024) & (K MT)

Table 32. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Application (2019-2024)

Table 33. Global Therapeutic Monoclonal Antibodies Drug Sales by Application (2019-2024) & (M USD)

Table 34. Global Therapeutic Monoclonal Antibodies Drug Market Share by Application (2019-2024)

Table 35. Global Therapeutic Monoclonal Antibodies Drug Sales Growth Rate by Application (2019-2024)

Table 36. Global Therapeutic Monoclonal Antibodies Drug Sales by Region (2019-2024) & (K MT)

Table 37. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region (2019-2024)

Table 38. North America Therapeutic Monoclonal Antibodies Drug Sales by Country (2019-2024) & (K MT)

Table 39. Europe Therapeutic Monoclonal Antibodies Drug Sales by Country (2019-2024) & (K MT)

Table 40. Asia Pacific Therapeutic Monoclonal Antibodies Drug Sales by Region (2019-2024) & (K MT)

Table 41. South America Therapeutic Monoclonal Antibodies Drug Sales by Country (2019-2024) & (K MT)

Table 42. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales by Region (2019-2024) & (K MT)

Table 43. Global Therapeutic Monoclonal Antibodies Drug Production (K MT) by Region (2019-2024)

Table 44. Global Therapeutic Monoclonal Antibodies Drug Revenue (US\$ Million) by Region (2019-2024)

Table 45. Global Therapeutic Monoclonal Antibodies Drug Revenue Market Share by

Region (2019-2024)

Table 46. Global Therapeutic Monoclonal Antibodies Drug Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 47. North America Therapeutic Monoclonal Antibodies Drug Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 48. Europe Therapeutic Monoclonal Antibodies Drug Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 49. Japan Therapeutic Monoclonal Antibodies Drug Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 50. China Therapeutic Monoclonal Antibodies Drug Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 51. AbbVie Therapeutic Monoclonal Antibodies Drug Basic Information

Table 52. AbbVie Therapeutic Monoclonal Antibodies Drug Product Overview

Table 53. AbbVie Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 54. AbbVie Business Overview

Table 55. AbbVie Therapeutic Monoclonal Antibodies Drug SWOT Analysis

Table 56. AbbVie Recent Developments

Table 57. Johnson and Johnson Therapeutic Monoclonal Antibodies Drug Basic Information

Table 58. Johnson and Johnson Therapeutic Monoclonal Antibodies Drug Product Overview

Table 59. Johnson and Johnson Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 60. Johnson and Johnson Business Overview

Table 61. Johnson and Johnson Therapeutic Monoclonal Antibodies Drug SWOT Analysis

Table 62. Johnson and Johnson Recent Developments

Table 63. Novartis Therapeutic Monoclonal Antibodies Drug Basic Information

Table 64. Novartis Therapeutic Monoclonal Antibodies Drug Product Overview

Table 65. Novartis Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 66. Novartis Therapeutic Monoclonal Antibodies Drug SWOT Analysis

Table 67. Novartis Business Overview

Table 68. Novartis Recent Developments

Table 69. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Basic Information

Table 70. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product Overview

Table 71. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

- Table 72. Gilead Sciences Business Overview
- Table 73. Gilead Sciences Recent Developments
- Table 74. Roche Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 75. Roche Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 76. Roche Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 77. Roche Business Overview
- Table 78. Roche Recent Developments
- Table 79. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 80. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 81. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 82. Bristol-Myers Squibb Business Overview
- Table 83. Bristol-Myers Squibb Recent Developments
- Table 84. Amgen Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 85. Amgen Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 86. Amgen Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 87. Amgen Business Overview
- Table 88. Amgen Recent Developments
- Table 89. AstraZeneca Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 90. AstraZeneca Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 91. AstraZeneca Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 92. AstraZeneca Business Overview
- Table 93. AstraZeneca Recent Developments
- Table 94. Merck and Co Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 95. Merck and Co Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 96. Merck and Co Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 97. Merck and Co Business Overview
- Table 98. Merck and Co Recent Developments
- Table 99. Takeda Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 100. Takeda Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 101. Takeda Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 102. Takeda Business Overview

- Table 103. Takeda Recent Developments
- Table 104. Merck KGaA Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 105. Merck KGaA Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 106. Merck KGaA Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 107. Merck KGaA Business Overview
- Table 108. Merck KGaA Recent Developments
- Table 109. Seagen Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 110. Seagen Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 111. Seagen Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 112. Seagen Business Overview
- Table 113. Seagen Recent Developments
- Table 114. Eli Lilly Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 115. Eli Lilly Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 116. Eli Lilly Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 117. Eli Lilly Business Overview
- Table 118. Eli Lilly Recent Developments
- Table 119. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 120. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 121. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 122. Ono Pharmaceutical Business Overview
- Table 123. Ono Pharmaceutical Recent Developments
- Table 124. Pfizer Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 125. Pfizer Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 126. Pfizer Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 127. Pfizer Business Overview
- Table 128. Pfizer Recent Developments
- Table 129. Regeneron Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 130. Regeneron Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 131. Regeneron Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 132. Regeneron Business Overview
- Table 133. Regeneron Recent Developments

- Table 134. Innovent Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 135. Innovent Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 136. Innovent Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 137. Innovent Business Overview
- Table 138. Innovent Recent Developments
- Table 139. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Basic Information
- Table 140. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product Overview
- Table 141. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
- Table 142. Hengrui Medicine Business Overview
- Table 143. Hengrui Medicine Recent Developments
- Table 144. Global Therapeutic Monoclonal Antibodies Drug Sales Forecast by Region (2025-2032) & (K MT)
- Table 145. Global Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Region (2025-2032) & (M USD)
- Table 146. North America Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2025-2032) & (K MT)
- Table 147. North America Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2025-2032) & (M USD)
- Table 148. Europe Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2025-2032) & (K MT)
- Table 149. Europe Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2025-2032) & (M USD)
- Table 150. Asia Pacific Therapeutic Monoclonal Antibodies Drug Sales Forecast by Region (2025-2032) & (K MT)
- Table 151. Asia Pacific Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Region (2025-2032) & (M USD)
- Table 152. South America Therapeutic Monoclonal Antibodies Drug Sales Forecast by Country (2025-2032) & (K MT)
- Table 153. South America Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2025-2032) & (M USD)
- Table 154. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Consumption Forecast by Country (2025-2032) & (Units)
- Table 155. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Country (2025-2032) & (M USD)
- Table 156. Global Therapeutic Monoclonal Antibodies Drug Sales Forecast by Type

(2025-2032) & (K MT)

Table 157. Global Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Type (2025-2032) & (M USD)

Table 158. Global Therapeutic Monoclonal Antibodies Drug Price Forecast by Type (2025-2032) & (USD/MT)

Table 159. Global Therapeutic Monoclonal Antibodies Drug Sales (K MT) Forecast by Application (2025-2032)

Table 160. Global Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Application (2025-2032) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Therapeutic Monoclonal Antibodies Drug

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Therapeutic Monoclonal Antibodies Drug Market Size (M USD), 2019-2032

Figure 5. Global Therapeutic Monoclonal Antibodies Drug Market Size (M USD) (2019-2032)

Figure 6. Global Therapeutic Monoclonal Antibodies Drug Sales (K MT) & (2019-2032)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Therapeutic Monoclonal Antibodies Drug Market Size by Country (M USD)

Figure 11. Therapeutic Monoclonal Antibodies Drug Sales Share by Manufacturers in 2023

Figure 12. Global Therapeutic Monoclonal Antibodies Drug Revenue Share by Manufacturers in 2023

Figure 13. Therapeutic Monoclonal Antibodies Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 14. Global Market Therapeutic Monoclonal Antibodies Drug Average Price (USD/MT) of Key Manufacturers in 2023

Figure 15. The Global 5 and 10 Largest Players: Market Share by Therapeutic Monoclonal Antibodies Drug Revenue in 2023

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Therapeutic Monoclonal Antibodies Drug Market Share by Type

Figure 18. Sales Market Share of Therapeutic Monoclonal Antibodies Drug by Type (2019-2024)

Figure 19. Sales Market Share of Therapeutic Monoclonal Antibodies Drug by Type in 2023

Figure 20. Market Size Share of Therapeutic Monoclonal Antibodies Drug by Type (2019-2024)

Figure 21. Market Size Market Share of Therapeutic Monoclonal Antibodies Drug by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Therapeutic Monoclonal Antibodies Drug Market Share by Application

Figure 24. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by

Application (2019-2024)

Figure 25. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Application in 2023

Figure 26. Global Therapeutic Monoclonal Antibodies Drug Market Share by Application (2019-2024)

Figure 27. Global Therapeutic Monoclonal Antibodies Drug Market Share by Application in 2023

Figure 28. Global Therapeutic Monoclonal Antibodies Drug Sales Growth Rate by Application (2019-2024)

Figure 29. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region (2019-2024)

Figure 30. North America Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 31. North America Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country in 2023

Figure 32. U.S. Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 33. Canada Therapeutic Monoclonal Antibodies Drug Sales (K MT) and Growth Rate (2019-2024)

Figure 34. Mexico Therapeutic Monoclonal Antibodies Drug Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 36. Europe Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country in 2023

Figure 37. Germany Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 38. France Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 39. U.K. Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 40. Italy Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 41. Russia Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 42. Asia Pacific Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (K MT)

Figure 43. Asia Pacific Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region in 2023

Figure 44. China Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 45. Japan Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 46. South Korea Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 47. India Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 48. Southeast Asia Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 49. South America Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (K MT)

Figure 50. South America Therapeutic Monoclonal Antibodies Drug Sales Market Share by Country in 2023

Figure 51. Brazil Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 52. Argentina Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 53. Columbia Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 54. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (K MT)

Figure 55. Middle East and Africa Therapeutic Monoclonal Antibodies Drug Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 57. UAE Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 58. Egypt Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 59. Nigeria Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 60. South Africa Therapeutic Monoclonal Antibodies Drug Sales and Growth Rate (2019-2024) & (K MT)

Figure 61. Global Therapeutic Monoclonal Antibodies Drug Production Market Share by Region (2019-2024)

Figure 62. North America Therapeutic Monoclonal Antibodies Drug Production (K MT) Growth Rate (2019-2024)

Figure 63. Europe Therapeutic Monoclonal Antibodies Drug Production (K MT) Growth

Rate (2019-2024)

Figure 64. Japan Therapeutic Monoclonal Antibodies Drug Production (K MT) Growth Rate (2019-2024)

Figure 65. China Therapeutic Monoclonal Antibodies Drug Production (K MT) Growth Rate (2019-2024)

Figure 66. Global Therapeutic Monoclonal Antibodies Drug Sales Forecast by Volume (2019-2032) & (K MT)

Figure 67. Global Therapeutic Monoclonal Antibodies Drug Market Size Forecast by Value (2019-2032) & (M USD)

Figure 68. Global Therapeutic Monoclonal Antibodies Drug Sales Market Share Forecast by Type (2025-2032)

Figure 69. Global Therapeutic Monoclonal Antibodies Drug Market Share Forecast by Type (2025-2032)

Figure 70. Global Therapeutic Monoclonal Antibodies Drug Sales Forecast by Application (2025-2032)

Figure 71. Global Therapeutic Monoclonal Antibodies Drug Market Share Forecast by Application (2025-2032)

I would like to order

Product name: Global Therapeutic Monoclonal Antibodies Drug Market Research Report 2024, Forecast to 2032

Product link: <https://marketpublishers.com/r/G7107ADF68CCEN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7107ADF68CCEN.html>